Investigation of antibody dependent cellular cytotoxicity as a mechanism of action for a novel anti-PD-L1 monoclonal antibody

Ítems similars

• Antibody-dependent cellular cytotoxicity (ADCC) activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells
  per: Boyerinas, Benjamin, et al.
  Publicat: (2015)
• Anti-tumor effects of anti-PD-L1 therapy in an orthotopic bladder tumor model
  per: Lyon, Amanda, et al.
  Publicat: (2014)
• Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab
  per: Fujii, Rika, et al.
  Publicat: (2016)
• Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
  per: Donahue, Renee N., et al.
  Publicat: (2017)
• Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
  per: Italia Grenga, et al.
  Publicat: (2017-11-01)